Skip to main content
Erschienen in: Cancer Chemotherapy and Pharmacology 3/2004

01.09.2004 | Original Article

Effect of carcinomatosis and intraperitoneal 5-fluorouracil on peritoneal blood flow modulated by vasopressin in the rat as measured with the 133Xe-clearance technique

verfasst von: M. Öman, J. Tölli, P. Naredi, L. O. Hafström

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 3/2004

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Intraperitoneal administration of 5-fluorouracil for the treatment of gastrointestinal malignancies results in a greater total drug exposure in the peritoneal fluid than in plasma. Drugs are eliminated from the peritoneal cavity mainly by capillaries leading to the portal venous system and to a lesser extent by lymphatics. The drug itself and the presence of peritoneal carcinomatosis may affect elimination of the drug. The 133Xe-clearance technique allows the influence of a vasoactive agent on the peritoneal blood flow to be estimated with minimal invasiveness. The aim of the present study was to explore whether intraperitoneal 5-FU or peritoneal carcinomatosis affects the peritoneal blood flow and its reactivity to intravenous vasopressin, as measured indirectly with the 133Xe-clearance technique.

Methods

The animals used in this study were 63 Wistar-Fu (W-Fu) rats and 67 Lister-Hooded (LH) rats. On day 0, either 5-FU at 25 mg/kg body weight in 25 ml/kg isotonic saline was instilled intraperitoneally, or 1×105 syngeneic tumour cells were inoculated intraperitoneally. On days 1, 2 and 3 in the 5-FU-treated rats, and on days 12–16 in rats inoculated with tumour cells, peritoneal blood flow was analysed with the 133Xe-clearance technique, before and during intravenous infusion of vasopressin at 0.07 IU/min/kg body weight.

Results

The basal 133Xe-clearance before administration of vasopressin was similar in all groups except in the LH rats treated with 5-FU in which it was significantly lower. Infusion of vasopressin induced a significant decrease in 133Xe-clearance of the same magnitude in controls and in tumour-bearing rats. In the rats given intraperitoneal 5-FU, vasopressin did not reduce the 133Xe-clearance the first day after administration of 5-FU.

Conclusions

Intravenous vasopressin at 0.07 IU/min/kg decreased peritoneal blood flow as measured indirectly with the 133Xe-clearance method. Intraperitoneal 5-FU abrogated the reduction in peritoneal blood flow with intravenous vasopressin the first day after treatment. In contrast, the presence of peritoneal carcinomatosis did not influence peritoneal blood flow, nor the effect of vasopressin
Literatur
1.
Zurück zum Zitat Atkins CD (2003) Intraperitoneal chemotherapy for stage III ovarian cancer. Clin Oncol 21:957CrossRef Atkins CD (2003) Intraperitoneal chemotherapy for stage III ovarian cancer. Clin Oncol 21:957CrossRef
2.
Zurück zum Zitat Balthasar JP, Fung HL (1996) Pharmacokinetic and pharmacodynamic optimization of intraperitoneal chemotherapy. Life Sci 58:535CrossRefPubMed Balthasar JP, Fung HL (1996) Pharmacokinetic and pharmacodynamic optimization of intraperitoneal chemotherapy. Life Sci 58:535CrossRefPubMed
3.
Zurück zum Zitat Cunliffe WJ, Sugarbaker PH (1989) Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg 76:1082PubMed Cunliffe WJ, Sugarbaker PH (1989) Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg 76:1082PubMed
4.
Zurück zum Zitat Dietz DW, Casillas S, Jones SC, Milsom JW (1998) Vasopressin selectively increases 5-fluorouracil uptake by colorectal liver metastases following hepatic artery bolus infusion. J Surg Res 77:150CrossRefPubMed Dietz DW, Casillas S, Jones SC, Milsom JW (1998) Vasopressin selectively increases 5-fluorouracil uptake by colorectal liver metastases following hepatic artery bolus infusion. J Surg Res 77:150CrossRefPubMed
5.
Zurück zum Zitat El Malt M, Ceelen W, van den Broecke C, Cuvelier C, Van Belle S, De Neve W, de Hemptinne B, Pattyn P (2001) Healing of experimental colonic anastomoses: effects of combined preoperative high-dose radiotherapy and intraperitoneal 5-fluorouracil. Int J Cancer 96:297CrossRefPubMed El Malt M, Ceelen W, van den Broecke C, Cuvelier C, Van Belle S, De Neve W, de Hemptinne B, Pattyn P (2001) Healing of experimental colonic anastomoses: effects of combined preoperative high-dose radiotherapy and intraperitoneal 5-fluorouracil. Int J Cancer 96:297CrossRefPubMed
6.
Zurück zum Zitat Gyves JW, Ensminger WD, Stetson P, Niederhuber JE, Meyer M, Walker S, Janis MA, Gilbertson S (1984) Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system. Clin Pharmacol Ther 35:83PubMed Gyves JW, Ensminger WD, Stetson P, Niederhuber JE, Meyer M, Walker S, Janis MA, Gilbertson S (1984) Constant intraperitoneal 5-fluorouracil infusion through a totally implanted system. Clin Pharmacol Ther 35:83PubMed
7.
Zurück zum Zitat Hafstrom L, Nobin A, Persson B, Sundqvist K (1980) Effects of catecholamines on cardiovascular response and blood flow distribution to normal tissue and liver tumors in rats. Cancer Res 40:481 Hafstrom L, Nobin A, Persson B, Sundqvist K (1980) Effects of catecholamines on cardiovascular response and blood flow distribution to normal tissue and liver tumors in rats. Cancer Res 40:481
8.
Zurück zum Zitat Hugander A, Bolmsjo M, Hafstrom L, Persson B (1983) Liver blood flow studies during local hyperthermia. An experimental study in rats. Clin Oncol 9:303PubMed Hugander A, Bolmsjo M, Hafstrom L, Persson B (1983) Liver blood flow studies during local hyperthermia. An experimental study in rats. Clin Oncol 9:303PubMed
9.
Zurück zum Zitat Iwao T, Toyonaga A, Oho K, Shigemori H, Sakai T, Tayama C, Masumoto H, Sato M, Tanikawa K (1996) Effect of vasopressin on esophageal varices blood flow in patients with cirrhosis: comparisons with the effects on portal vein and superior mesenteric artery blood flow. J Hepatol 25:491CrossRefPubMed Iwao T, Toyonaga A, Oho K, Shigemori H, Sakai T, Tayama C, Masumoto H, Sato M, Tanikawa K (1996) Effect of vasopressin on esophageal varices blood flow in patients with cirrhosis: comparisons with the effects on portal vein and superior mesenteric artery blood flow. J Hepatol 25:491CrossRefPubMed
10.
Zurück zum Zitat Janunger KG, Hafstrom L, Nygren P, Glimelius B (2001) A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 40:309CrossRefPubMed Janunger KG, Hafstrom L, Nygren P, Glimelius B (2001) A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol 40:309CrossRefPubMed
11.
Zurück zum Zitat Kjartansson I (1976) Tumour circulation. An experimental study in the rat with a comparison of different methods for estimation of tumour blood flow. Acta Chir Scand Suppl 471:1PubMed Kjartansson I (1976) Tumour circulation. An experimental study in the rat with a comparison of different methods for estimation of tumour blood flow. Acta Chir Scand Suppl 471:1PubMed
12.
Zurück zum Zitat Lindner P, Heath DD, Shalinsky DR, Howell SB, Naredi P, Hafstrom L (1993) Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide. Surg Oncol 2:105CrossRefPubMed Lindner P, Heath DD, Shalinsky DR, Howell SB, Naredi P, Hafstrom L (1993) Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide. Surg Oncol 2:105CrossRefPubMed
13.
Zurück zum Zitat Lindner P, Heath D, Howell S, Naredi P, Hafstrom L (1996) Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. Clin Cancer Res 2:311PubMed Lindner P, Heath D, Howell S, Naredi P, Hafstrom L (1996) Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration. Clin Cancer Res 2:311PubMed
14.
Zurück zum Zitat Lopes Cardozo AM, Gupta A, Koppe MJ, Meijer S, van Leeuwen PA, Beelen RJ, Bleichrodt RP (2001) Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol 27:359CrossRefPubMed Lopes Cardozo AM, Gupta A, Koppe MJ, Meijer S, van Leeuwen PA, Beelen RJ, Bleichrodt RP (2001) Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol 27:359CrossRefPubMed
15.
Zurück zum Zitat Lubbe AS, Herrmann R, Riess H, Huhn D (1993) Microcirculatory effects of hyperthermia and 5-fluorouracil in the skin of nude mice. Int J Microcirc Clin Exp 13(3):205PubMed Lubbe AS, Herrmann R, Riess H, Huhn D (1993) Microcirculatory effects of hyperthermia and 5-fluorouracil in the skin of nude mice. Int J Microcirc Clin Exp 13(3):205PubMed
16.
Zurück zum Zitat Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4:277CrossRefPubMed Markman M (2003) Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 4:277CrossRefPubMed
17.
Zurück zum Zitat Naredi P, Lindner P, Holmberg SB, Soderberg R, Carlsson G, Gustavsson B, Jacobsson L, Hafstrom L (1992) The influence of hepatic artery ligation and of vasopressin on liver tumour blood flow in rats. J Surg Oncol 50:70PubMed Naredi P, Lindner P, Holmberg SB, Soderberg R, Carlsson G, Gustavsson B, Jacobsson L, Hafstrom L (1992) The influence of hepatic artery ligation and of vasopressin on liver tumour blood flow in rats. J Surg Oncol 50:70PubMed
18.
Zurück zum Zitat Oman M, Blind P, Naredi P, Gustavsson B, Hafstrom L (2001) Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV. Eur J Surg Oncol 27:477CrossRefPubMed Oman M, Blind P, Naredi P, Gustavsson B, Hafstrom L (2001) Treatment of non-resectable pancreatic cancer with intraperitoneal 5-FU and leucovorin IV. Eur J Surg Oncol 27:477CrossRefPubMed
19.
Zurück zum Zitat Oman M, Tolli J, Blind PJ, Naredi P, Hafstrom LO (2004) Intraperitoneal Xe-clearance—a method to estimate the effect of vasopressin on peritoneal blood flow in rats. Hepatogastroenterology (in press) Oman M, Tolli J, Blind PJ, Naredi P, Hafstrom LO (2004) Intraperitoneal Xe-clearance—a method to estimate the effect of vasopressin on peritoneal blood flow in rats. Hepatogastroenterology (in press)
20.
Zurück zum Zitat Ottow RT, Steller EP, Sugarbaker PH, Wesley RA, Rosenberg SA (1987) Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models. Cell Immunol 104:366PubMed Ottow RT, Steller EP, Sugarbaker PH, Wesley RA, Rosenberg SA (1987) Immunotherapy of intraperitoneal cancer with interleukin 2 and lymphokine-activated killer cells reduces tumor load and prolongs survival in murine models. Cell Immunol 104:366PubMed
21.
Zurück zum Zitat Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW Jr, Myers CE (1981) Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41:1916PubMed Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW Jr, Myers CE (1981) Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 41:1916PubMed
22.
Zurück zum Zitat Steele G Jr, Sjogren HO (1974) Cross-reacting tumor-associated antigen(s) among chemically induced rat colon carcinomas. Cancer Res 34:1801PubMed Steele G Jr, Sjogren HO (1974) Cross-reacting tumor-associated antigen(s) among chemically induced rat colon carcinomas. Cancer Res 34:1801PubMed
23.
Zurück zum Zitat Sugarbaker PH, Landy D, Pascal R (1990) Intraperitoneal chemotherapy for peritoneal carcinomatosis from colonic or appendiceal cystadenocarcinoma: rationale and results of treatment. Prog Clin Biol Res 354B:141PubMed Sugarbaker PH, Landy D, Pascal R (1990) Intraperitoneal chemotherapy for peritoneal carcinomatosis from colonic or appendiceal cystadenocarcinoma: rationale and results of treatment. Prog Clin Biol Res 354B:141PubMed
Metadaten
Titel
Effect of carcinomatosis and intraperitoneal 5-fluorouracil on peritoneal blood flow modulated by vasopressin in the rat as measured with the 133Xe-clearance technique
verfasst von
M. Öman
J. Tölli
P. Naredi
L. O. Hafström
Publikationsdatum
01.09.2004
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 3/2004
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-004-0812-3

Weitere Artikel der Ausgabe 3/2004

Cancer Chemotherapy and Pharmacology 3/2004 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.